Bendamustine in advanced multiple myeloma previously treated with bortezomid and lenalidomide containing regimen

被引：0
|
作者：
Lehenbauer-Dehm, S. [1 ]
Alex, M. [1 ]
Pecher, G. [1 ]
Blau, I [2 ]
Eucker, J. [1 ]
Possinger, K. [1 ]
Scholz, C. [1 ]
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Charite Campus Benjamin Franklin, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [21] Advanced practice nurse management in multiple myeloma treated with lenalidomide dexamethasone: "A new challenge"?
    Sapet, M.
    Migala, C.
    Daguenet, E.
    Collet, P.
    Boussoualim, K.
    Thomas, T.
    Guyotat, D.
    Augeul-Meunier, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1270 - S1271
  • [22] EDA-V in advanced multiple myeloma patients previously treated with thalidomide
    Polloni, C.
    Offidani, M.
    Corvatta, L.
    Piersantelli, M. N.
    Catarini, M.
    Brunori, M.
    Alesiani, F.
    Burattini, M.
    Leoni, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 145 - 146
  • [23] PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE
    Tarantolo, S. R.
    McSweeney, P. A.
    Micallef, I. N. M.
    Klein, L. M.
    Calandra, G.
    Huebner, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 37 - 37
  • [24] PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE
    Micallef, I. N. N.
    Tarantolo, S. R.
    McSweeney, P. A.
    Kjein, L. M.
    Calandra, G.
    Huebner, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 292 - 292
  • [25] Autologous peripheral blood stem cell collection and transplantation in patients with multiple myeloma previously treated with thalidomide and/or lenalidomide using a cyclophosphamide-based mobilization regimen
    Grubovic, R. M.
    Alavi, A.
    Schiller, G. J.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S123 - S123
  • [26] Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen
    Berenson, James R.
    Cohen, Alexa
    Spektor, Tanya M.
    Lashkari, Ashkan
    Mackintosh, Roy
    Bessudo, Alberto
    Jhangiani, Haresh
    Gabrail, Nashat
    Nakhoul, Ibrahim
    Kubba, Samir
    Neidhart, Jeffrey D.
    Tina, Maluso
    Swift, Regina
    Vescio, Robert
    BLOOD, 2017, 130
  • [27] THOMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE OR THALIDOMIDE
    Palmaro, A.
    Despas, F.
    Lapeyre-Mestre, M.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E65 - E65
  • [28] Early time therapy with Lenalidomide for advanced multiple myeloma?
    Ronge, Renate
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (05) : 174 - 174
  • [29] Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma
    Kumar, Shaji K.
    Krishnan, Amrita
    LaPlant, Betsy
    Laumann, Kristina
    Roy, Vivek
    Zimmerman, Todd
    Gertz, Morie A.
    Buadi, Francis K.
    Goldstein, Keith Stockerl
    Birgin, Ann
    Fiala, Mark
    Duarte, Lupe
    Maharaj, Michelle
    Levy, Joan
    Vij, Ravi
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (12) : 1106 - 1110
  • [30] PAD plus lenalidomide in multiple myeloma - a promising four-drug regimen in newly diagnosed and advanced disease
    Schreder, M.
    Danhof, S.
    Rasche, L.
    Strifler, S.
    Einsele, H.
    Knop, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 290 - 290
12345